{"name":"Celltrion","slug":"celltrion","ticker":"068270.KS","exchange":"KRX","domain":"celltrion.com","description":"Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year.","hq":"Incheon, South Korea","founded":2002,"employees":"~1,500","ceo":"Seo Jung-jin","sector":"Biosimilars / Biologics","stockPrice":202000,"stockChange":8300,"stockChangePercent":4.28,"marketCap":"$44.2T","metrics":{"revenue":4162495184896,"revenueGrowth":25.1,"grossMargin":59.3,"rdSpend":0,"netIncome":1029613355008,"cash":1239106584576,"dividendYield":0.39,"peRatio":28.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-02","label":"VEGZELMA Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-31","label":"VEGZELMA Phase 3 readout (Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-31","label":"VEGZELMA Phase 3 readout (Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-30","label":"HERZUMA Phase 3 readout (Breast Neoplasms, Breast Cancer)","drug":"HERZUMA","drugSlug":"trastuzumab-pkrb","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-06-01","label":"VEGZELMA Phase 3 readout (Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-15","label":"VEGZELMA Phase 2 readout (Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-01-01","label":"VEGZELMA Phase 3 readout (Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-07-01","label":"VEGZELMA Phase 3 readout (Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2029-03-10","label":"VEGZELMA Phase 3 readout (Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-02-28","label":"VEGZELMA Phase 3 readout (Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-12-31","label":"VEGZELMA Phase 3 readout (Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma)","drug":"VEGZELMA","drugSlug":"bevacizumab-adcd","type":"phase3_readout","sentiment":"neutral"},{"date":"2028-06-01","label":"CT-P13 patent cliff ($1.5B at risk)","drug":"CT-P13","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"CT-P39 patent cliff ($19.2B at risk)","drug":"CT-P39","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"AML Y mg","genericName":"AML Y mg","slug":"aml-y-mg","indication":"Treatment of relapsed or refractory follicular lymphoma","status":"phase_3"},{"name":"CT-P16","genericName":"CT-P16","slug":"ct-p16","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CT-P17","genericName":"CT-P17","slug":"ct-p17","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CT-P39","genericName":"CT-P39","slug":"ct-p39","indication":"Non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"CT-P41","genericName":"CT-P41","slug":"ct-p41","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"CT-P42","genericName":"CT-P42","slug":"ct-p42","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CT-P43","genericName":"CT-P43","slug":"ct-p43","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"CT-P44(Daratumumab)","genericName":"CT-P44(Daratumumab)","slug":"ct-p44-daratumumab","indication":"Multiple myeloma (in combination with standard therapies)","status":"phase_3"},{"name":"CT-P47","genericName":"CT-P47","slug":"ct-p47","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CT-P51","genericName":"CT-P51","slug":"ct-p51","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"CT-P53","genericName":"CT-P53","slug":"ct-p53","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"CT-P55","genericName":"CT-P55","slug":"ct-p55","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"Darzalex Faspro(Daratumumab)","genericName":"Darzalex Faspro(Daratumumab)","slug":"darzalex-faspro-daratumumab","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"EU-approved Keytruda","genericName":"EU-approved Keytruda","slug":"eu-approved-keytruda","indication":"Metastatic melanoma","status":"phase_3"},{"name":"US-Ocrevus","genericName":"US-Ocrevus","slug":"us-ocrevus","indication":"Multiple sclerosis (relapsing and primary progressive forms)","status":"phase_3"},{"name":"US-licensed Prolia","genericName":"US-licensed Prolia","slug":"us-licensed-prolia","indication":"Treatment of osteoporosis in postmenopausal women at high risk of fracture","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"immunology","drugs":[{"name":"Humira SC","genericName":"Humira SC","slug":"humira-sc","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-L03","genericName":"CT-L03","slug":"ct-l03","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P10","genericName":"CT-P10","slug":"ct-p10","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P13 SC (Infliximab)","genericName":"CT-P13 SC (Infliximab)","slug":"ct-p13-sc-infliximab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P13 SC Auto-injector","genericName":"CT-P13 SC Auto-injector","slug":"ct-p13-sc-auto-injector","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P17 SC","genericName":"CT-P17 SC","slug":"ct-p17-sc","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P17 SC AI (adalimumab)","genericName":"CT-P17 SC AI (adalimumab)","slug":"ct-p17-sc-ai-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P47 AI (tocilizumab)","genericName":"CT-P47 AI (tocilizumab)","slug":"ct-p47-ai-tocilizumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P47 PFS (tocilizumab)","genericName":"CT-P47 PFS (tocilizumab)","slug":"ct-p47-pfs-tocilizumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CT-P6","genericName":"CT-P6","slug":"ct-p6","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"EU-approved Cosentyx","genericName":"EU-approved Cosentyx","slug":"eu-approved-cosentyx","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"EU-approved Humira","genericName":"EU-approved Humira","slug":"eu-approved-humira","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"US-licensed Humira","genericName":"US-licensed Humira","slug":"us-licensed-humira","indication":"Rheumatoid Arthritis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"neuroscience","drugs":[{"name":"AVTOZMA","genericName":"TOCILIZUMAB-ANOH","slug":"tocilizumab-anoh","indication":"Other","status":"marketed"},{"name":"CT-P27","genericName":"CT-P27","slug":"ct-p27","indication":"Other","status":"phase_2"},{"name":"EYDENZELT","genericName":"AFLIBERCEPT-BOAV","slug":"aflibercept-boav","indication":"Other","status":"marketed"},{"name":"HERZUMA","genericName":"TRASTUZUMAB-PKRB","slug":"trastuzumab-pkrb","indication":"Other","status":"marketed"},{"name":"Placebo Auto-Injector","genericName":"Placebo Auto-Injector","slug":"placebo-auto-injector","indication":"Clinical trial control/comparator (not a therapeutic indication)","status":"marketed"},{"name":"STEQEYMA","genericName":"USTEKINUMAB-STBA","slug":"ustekinumab-stba","indication":"Other","status":"marketed"},{"name":"TRUXIMA","genericName":"RITUXIMAB-ABBS","slug":"rituximab-abbs","indication":"Other","status":"marketed"},{"name":"US-licensed Xolair","genericName":"US-licensed Xolair","slug":"us-licensed-xolair","indication":"Other","status":"phase_1"},{"name":"VEGZELMA","genericName":"BEVACIZUMAB-ADCD","slug":"bevacizumab-adcd","indication":"Other","status":"marketed"},{"name":"YUFLYMA","genericName":"ADALIMUMAB-AATY","slug":"adalimumab-aaty","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Regkirona","genericName":"REGDANVIMAB","slug":"regdanvimab","indication":"COVID-19","status":"marketed"},{"name":"AZM X mg","genericName":"AZM X mg","slug":"azm-x-mg","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"CT-P59","genericName":"CT-P59","slug":"ct-p59","indication":"Treatment of COVID-19","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"AZM X mg + AML Y mg","genericName":"AZM X mg + AML Y mg","slug":"azm-x-mg-aml-y-mg","indication":"Hypertension (essential hypertension in adults)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"EU-Ocrevus","genericName":"EU-Ocrevus","slug":"eu-ocrevus","indication":"Multiple sclerosis (relapsing and progressive forms)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"EU-approved Xolair","genericName":"EU-approved Xolair","slug":"eu-approved-xolair","indication":"Moderate to severe allergic asthma","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"Pioglitazone + Alogliptin","genericName":"Pioglitazone + Alogliptin","slug":"pioglitazone-alogliptin","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"AML Y mg","genericName":"AML Y mg","slug":"aml-y-mg","phase":"phase_3","mechanism":"AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation.","indications":["Treatment of relapsed or refractory follicular lymphoma"],"catalyst":""},{"name":"Humira SC","genericName":"Humira SC","slug":"humira-sc","phase":"phase_3","mechanism":"Humira SC is a subcutaneous formulation of adalimumab, a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Regkirona","genericName":"REGDANVIMAB","slug":"regdanvimab","phase":"marketed","mechanism":"Monoclonal antibody","indications":["COVID-19"],"catalyst":""},{"name":"AVTOZMA","genericName":"TOCILIZUMAB-ANOH","slug":"tocilizumab-anoh","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"AZM X mg","genericName":"AZM X mg","slug":"azm-x-mg","phase":"phase_3","mechanism":"Azithromycin is a macrolide antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit.","indications":["Community-acquired pneumonia","Chronic bronchitis","Acute exacerbations of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"AZM X mg + AML Y mg","genericName":"AZM X mg + AML Y mg","slug":"azm-x-mg-aml-y-mg","phase":"phase_3","mechanism":"AZM (azilsartan) is an angiotensin II receptor blocker and AML (amlodipine) is a calcium channel blocker; together they reduce blood pressure through complementary vasodilatory pathways.","indications":["Hypertension (essential hypertension in adults)"],"catalyst":""},{"name":"CT-L03","genericName":"CT-L03","slug":"ct-l03","phase":"phase_3","mechanism":"CT-L03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CT-P10","genericName":"CT-P10","slug":"ct-p10","phase":"phase_3","mechanism":"CT-P10 is a monoclonal antibody that binds to and inhibits TNF-alpha, reducing inflammatory signaling in autoimmune and inflammatory diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"CT-P13 SC (Infliximab)","genericName":"CT-P13 SC (Infliximab)","slug":"ct-p13-sc-infliximab","phase":"phase_3","mechanism":"CT-P13 SC is a subcutaneous formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"CT-P13 SC Auto-injector","genericName":"CT-P13 SC Auto-injector","slug":"ct-p13-sc-auto-injector","phase":"phase_3","mechanism":"CT-P13 SC is a subcutaneous auto-injector formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CT-P16","genericName":"CT-P16","slug":"ct-p16","phase":"phase_3","mechanism":"CT-P16 is a monoclonal antibody that binds to and blocks programmed death ligand 1 (PD-L1), enhancing anti-tumor immune responses by releasing the inhibition of T cells.","indications":["Non-small cell lung cancer","Urothelial carcinoma"],"catalyst":""},{"name":"CT-P17","genericName":"CT-P17","slug":"ct-p17","phase":"phase_3","mechanism":"CT-P17 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"CT-P17 SC","genericName":"CT-P17 SC","slug":"ct-p17-sc","phase":"phase_3","mechanism":"CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CT-P17 SC AI (adalimumab)","genericName":"CT-P17 SC AI (adalimumab)","slug":"ct-p17-sc-ai-adalimumab","phase":"phase_3","mechanism":"CT-P17 SC AI is a subcutaneous adalimumab biosimilar that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"CT-P27","genericName":"CT-P27","slug":"ct-p27","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CT-P39","genericName":"CT-P39","slug":"ct-p39","phase":"phase_3","mechanism":"CT-P39 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer (NSCLC)","Small cell lung cancer (SCLC)","Urothelial carcinoma","Triple-negative breast cancer (TNBC)"],"catalyst":""},{"name":"CT-P41","genericName":"CT-P41","slug":"ct-p41","phase":"phase_3","mechanism":"CT-P41 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)","HER2-positive gastric cancer"],"catalyst":""},{"name":"CT-P42","genericName":"CT-P42","slug":"ct-p42","phase":"phase_3","mechanism":"CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Urothelial carcinoma","Triple-negative breast cancer"],"catalyst":""},{"name":"CT-P43","genericName":"CT-P43","slug":"ct-p43","phase":"phase_3","mechanism":"CT-P43 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)"],"catalyst":""},{"name":"CT-P44(Daratumumab)","genericName":"CT-P44(Daratumumab)","slug":"ct-p44-daratumumab","phase":"phase_3","mechanism":"CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis.","indications":["Multiple myeloma (in combination with standard therapies)","Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"CT-P47","genericName":"CT-P47","slug":"ct-p47","phase":"phase_3","mechanism":"CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"CT-P47 AI (tocilizumab)","genericName":"CT-P47 AI (tocilizumab)","slug":"ct-p47-ai-tocilizumab","phase":"phase_3","mechanism":"CT-P47 is a biosimilar of tocilizumab that blocks the interleukin-6 (IL-6) receptor to reduce inflammatory signaling.","indications":["Rheumatoid arthritis","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease"],"catalyst":""},{"name":"CT-P47 PFS (tocilizumab)","genericName":"CT-P47 PFS (tocilizumab)","slug":"ct-p47-pfs-tocilizumab","phase":"phase_3","mechanism":"CT-P47 is a monoclonal antibody that blocks interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis"],"catalyst":""},{"name":"CT-P51","genericName":"CT-P51","slug":"ct-p51","phase":"phase_3","mechanism":"CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma"],"catalyst":""},{"name":"CT-P53","genericName":"CT-P53","slug":"ct-p53","phase":"phase_3","mechanism":"CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"CT-P55","genericName":"CT-P55","slug":"ct-p55","phase":"phase_3","mechanism":"CT-P55 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","indications":["HER2-positive metastatic breast cancer","HER2-positive early-stage breast cancer (adjuvant/neoadjuvant setting)"],"catalyst":""},{"name":"CT-P59","genericName":"CT-P59","slug":"ct-p59","phase":"phase_2","mechanism":"CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"CT-P6","genericName":"CT-P6","slug":"ct-p6","phase":"phase_3","mechanism":"CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Darzalex Faspro(Daratumumab)","genericName":"Darzalex Faspro(Daratumumab)","slug":"darzalex-faspro-daratumumab","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain multiple myeloma"],"catalyst":""},{"name":"EU-Ocrevus","genericName":"EU-Ocrevus","slug":"eu-ocrevus","phase":"phase_3","mechanism":"EU-Ocrevus is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","indications":["Multiple sclerosis (relapsing and progressive forms)","Granulomatosis with polyangiitis (GPA)","Microscopic polyangiitis (MPA)"],"catalyst":""},{"name":"EU-approved Cosentyx","genericName":"EU-approved Cosentyx","slug":"eu-approved-cosentyx","phase":"phase_3","mechanism":"Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated skin and joint diseases.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"EU-approved Humira","genericName":"EU-approved Humira","slug":"eu-approved-humira","phase":"phase_3","mechanism":"Humira is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key inflammatory cytokine driving autoimmune and inflammatory diseases.","indications":["Rheumatoid arthritis","Ankylosing spondylitis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"EU-approved Keytruda","genericName":"EU-approved Keytruda","slug":"eu-approved-keytruda","phase":"phase_3","mechanism":"Keytruda is a monoclonal antibody that blocks PD-1 on immune cells, allowing the immune system to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"EU-approved Xolair","genericName":"EU-approved Xolair","slug":"eu-approved-xolair","phase":"phase_3","mechanism":"Xolair is a monoclonal antibody that binds to immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.","indications":["Moderate to severe allergic asthma","Chronic idiopathic urticaria","Allergic rhinitis (in some markets)"],"catalyst":""},{"name":"EYDENZELT","genericName":"AFLIBERCEPT-BOAV","slug":"aflibercept-boav","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"HERZUMA","genericName":"TRASTUZUMAB-PKRB","slug":"trastuzumab-pkrb","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Pioglitazone + Alogliptin","genericName":"Pioglitazone + Alogliptin","slug":"pioglitazone-alogliptin","phase":"marketed","mechanism":"Pioglitazone improves insulin sensitivity by activating PPAR-γ, while alogliptin inhibits DPP-4 to increase incretin levels, together reducing blood glucose in type 2 diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Placebo Auto-Injector","genericName":"Placebo Auto-Injector","slug":"placebo-auto-injector","phase":"marketed","mechanism":"A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies.","indications":["Clinical trial control/comparator (not a therapeutic indication)"],"catalyst":""},{"name":"STEQEYMA","genericName":"USTEKINUMAB-STBA","slug":"ustekinumab-stba","phase":"marketed","mechanism":"Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.","indications":[],"catalyst":""},{"name":"TRUXIMA","genericName":"RITUXIMAB-ABBS","slug":"rituximab-abbs","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"US-Ocrevus","genericName":"US-Ocrevus","slug":"us-ocrevus","phase":"phase_3","mechanism":"US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation.","indications":["Multiple sclerosis (relapsing and primary progressive forms)","B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"US-licensed Humira","genericName":"US-licensed Humira","slug":"us-licensed-humira","phase":"phase_3","mechanism":"Humira is a monoclonal antibody that targets and binds to tumor necrosis factor-alpha (TNF-alpha), preventing it from interacting with its cell surface receptor and thereby reducing inflammation.","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Plaque Psoriasis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"US-licensed Prolia","genericName":"US-licensed Prolia","slug":"us-licensed-prolia","phase":"phase_3","mechanism":"Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.","indications":["Treatment of osteoporosis in postmenopausal women at high risk of fracture","Treatment of bone loss in patients with hormone ablation for non-metastatic prostate cancer"],"catalyst":""},{"name":"US-licensed Xolair","genericName":"US-licensed Xolair","slug":"us-licensed-xolair","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VEGZELMA","genericName":"BEVACIZUMAB-ADCD","slug":"bevacizumab-adcd","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"YUFLYMA","genericName":"ADALIMUMAB-AATY","slug":"adalimumab-aaty","phase":"marketed","mechanism":"","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Celltrion's CT-P39 biosimilar of Humira receives EU approval","summary":"The European Commission has granted marketing authorization to Celltrion's CT-P39, a biosimilar of AbbVie's Humira.","drugName":"CT-P39","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Celltrion reports Q3 2023 earnings","summary":"Celltrion has announced its Q3 2023 financial results, with revenue increasing 15% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Celltrion partners with Mylan to commercialize biosimilars in the US","summary":"Celltrion has entered into a partnership with Mylan to commercialize its biosimilars in the US market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNbTlJYUJUeVJjVUdOLWtJV2pEQjJxdzNSWkZ5alNEelFkWGtQMERRQlNEM0t6U0c2SzlEVGcyeEdMT3RWRHhucXdJX2wyM3lRSW9ZTmsycy0taGthWkZIa2VMelpZeU1RY2lmRzRYakRXbEVrRGNCdXNqZ3lDZFVlbTUyWVM5bHJRMS1xVklmMEZTLWZjUzJOZmtaX1F3eDNSODZJ?oc=5","date":"2026-04-05","type":"pipeline","source":"Seoul Economic Daily","summary":"Celltrion Says U.S. Pharma Tariff Impact \"Effectively Resolved\" via Local Production - Seoul Economic Daily","headline":"Celltrion Says U.S. Pharma Tariff Impact \"Effectively Resolved\" via Local Production","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQekg5YXhHc1RKX3VEMUFFU2dJMUlpMTZPSV9ObG9qOWdBenpjT1VBQ25zbS1iYV9TcmszcVMxUUVnWDlvMDJaQ3RKak5kMGNzTFVyNUVyYzdVOTFDOXl4eWFxaGNOdW1JMVRMbEk5MXhkNm1HVDhjU25rZUtFNzcwLTV6LUM5SWdUTWlRWWk0YnRGcG9idnlIUUlTSQ?oc=5","date":"2026-04-05","type":"pipeline","source":"Seoul Economic Daily","summary":"Korea Discusses Response to U.S. Section 232 Tariffs on Pharmaceuticals - Seoul Economic Daily","headline":"Korea Discusses Response to U.S. Section 232 Tariffs on Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPanZtbkNSYjF0OHVzR3l1Rk9sUTh2YzFZc25hTjV1bjZVYzlwWC1ISVlzcmJrNlJOVTdBTmZYbU9HWThobGExYi1IM2xaTFVTX2swS1dJcWlHVkE5UHQyWnpXOEJRX2d4dElCeUdNZTR1MjFiYjBqanhXU0pmSDZRQlMxMnFBajdfaENHMkVpVXo1N1VnNFA2dnl2dmlEOFk?oc=5","date":"2026-04-02","type":"earnings","source":"Seoul Economic Daily","summary":"K-Pharma and Bio Firms' Combined Revenue Tops 30 Trillion Won in 2024 - Seoul Economic Daily","headline":"K-Pharma and Bio Firms' Combined Revenue Tops 30 Trillion Won in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOd2sxMDhhODc5UFlVeE9HMlBmLUtmWmNRWnU5RzVsemt1cWJVZGZNR2d5Z1k1TF9sb0pVaWZiMjVsUl9oUW85QzZMakp2dTlUY3pLdmlYeGpqZ3BKRVBtd0t0R2wyVzFrVGlaRzc5ZVFxRnJraERpeGk1VGFESk9WVEVOUlBXXzlpTnExSmxfQzd3MzUtZkw2VmZhVTBaQQ?oc=5","date":"2026-04-02","type":"earnings","source":"Seoul Economic Daily","summary":"K-Pharma and Bio Revenue Tops 30 Trillion Won on New Drugs, Exports - Seoul Economic Daily","headline":"K-Pharma and Bio Revenue Tops 30 Trillion Won on New Drugs, Exports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPcHhtWkhENkw2c1dCQllBWDY1cy01NXY0XzktT2NZVFFGRTlmVHA4U19iVmV6b29jQmZfWktESFdNRDZFWW15Q01fTVlEd0JQVGdVNzRpU1ZFTUFBMEhvdk9kX09tVmZFa25kRnBVS1NWQUdlT2lIUzViZXYwOXNlOWlodk44S3JkLUNfZHZwVi1tN3h6M18ySm9vTWI?oc=5","date":"2026-03-31","type":"pipeline","source":"Seoul Economic Daily","summary":"Celltrion Launches Omriclo in Brazil, Accelerates Latin American Push - Seoul Economic Daily","headline":"Celltrion Launches Omriclo in Brazil, Accelerates Latin American Push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNNm4ybWxmSlZsZ253S3lqUlBaWVV4VWFzQm9jYjZDTm5zNlRHSWZOLThpM3ppcTUxM3prTGNQNWRjeXRGWmc3U3lZQW9LM19pcDdMVGpKX0tzd194OHp6XzNSMDZncTAxYXpVaVE0UkRYN2hEc2RieWZpQWtjclQwbllNNmlCR0U1a05zZUI4ZnlVRE44RDNla0h0UF8?oc=5","date":"2026-03-30","type":"pipeline","source":"Seoul Economic Daily","summary":"Top Investors Load Up on Bio and VC Stocks Amid Unending Market Turmoil - Seoul Economic Daily","headline":"Top Investors Load Up on Bio and VC Stocks Amid Unending Market Turmoil","sentiment":"neutral"}],"patents":[{"drugName":"CT-P13","drugSlug":"infliximab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"CT-P39","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":19200000000}],"drugCount":46,"phaseCounts":{"phase_3":33,"marketed":10,"phase_2":2,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Samsung Bioepis","Mylan","Pfizer"],"therapeuticFocus":["Autoimmune diseases","Inflammatory diseases"],"financials":null,"yahoo":{"currentPrice":202000,"previousClose":193700,"fiftyTwoWeekHigh":251000,"fiftyTwoWeekLow":144615.39,"fiftyTwoWeekRange":"144615.39 - 251000.0","fiftyDayAverage":216236,"twoHundredDayAverage":189470.5,"beta":0.4,"enterpriseValue":44979422494720,"forwardPE":28.3,"priceToBook":0,"priceToSales":10.62,"enterpriseToRevenue":10.81,"enterpriseToEbitda":30.98,"pegRatio":0.85,"ebitda":1452074336256,"ebitdaMargin":34.9,"freeCashflow":171784798208,"operatingCashflow":646050807808,"totalDebt":3729110335488,"debtToEquity":21.5,"currentRatio":1.39,"returnOnAssets":3.4,"returnOnEquity":5.9,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":24,"targetMeanPrice":254500,"targetHighPrice":290000,"targetLowPrice":170000,"dividendRate":750,"payoutRatio":0.16,"fiveYearAvgDividendYield":0,"exDividendDate":1766966400,"insiderHeldPercent":34.7,"institutionHeldPercent":18,"sharesOutstanding":218775332,"floatShares":144990782,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":18871.2,"bookValue":0,"officers":[{"age":60,"name":"Mr. Hyong-Gi  Kim","title":"Co-CEO & Internal Director"},{"age":64,"name":"Mr. Woo-Sung  Kee","title":"Co-CEO & Internal Director"},{"age":41,"name":"Mr. Jin-Seok  Seo","title":"Co-CEO & Inside Co-Chairman of the Board"},{"age":null,"name":"Mr. Stephen  Yeum","title":"Founder"},{"age":54,"name":"Mr. Min-Cheol  Shin","title":"Director of Finance"},{"age":54,"name":"Mr. Ji-Hoon  Choi","title":"Director of Legal Affairs"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.celltrion.com","phone":"82 3 2850 5000"}}